Endocyte recently announced it filed a registration statement with the SEC for an IPO of its common stock. Endocyte (see the April 20, 2010 LRTJ) develops targeted cancer therapeutics utilizing folate molecules –...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)